Digital Health Global
MARCH 1, 2023
The current B Capital global healthcare portfolio includes over 20 companies in the US, Asia and Europe, spanning early venture to late growth venture, across healthtech, digital health, biotech and medtech. With approximately $6.3
Digital Health Global
JUNE 20, 2023
Dr. Rhodes brings more than 25 years of drug discovery, company building and strategic leadership in the biotech industry, including 18 years at Biogen. has been a senior executive/CEO, as well as a chairman, board member, and entrepreneur in multiple public and private biotech and pharma companies in the U.S. Jane Rhodes, Ph.D.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lloyd Price
JULY 5, 2018
For many biotech companies, mergers and acquisitions have become a cornerstone in building a robust pipeline that can ensure positive growth for years to come. 2017 was considered to be a lean year for M&A in biotech. BioSpace reported in January that there were 101 deals, down from 166 in 2015.
Digital Health Global
MAY 4, 2023
Founded in 2015 and headquartered in New York, m+a offers full-service capabilities to a diverse group of blue-chip pharma, biotech, and digital health companies across a range of therapeutic categories, including rare diseases, mental health, oncology, CNS, dermatology, and more. Terms of the transaction were not disclosed.
Insulin Nation
MAY 1, 2015
in 2015 or 2016, and it would be projected to generate $3 billion a year in global sales. According to a Fierce Biotech report on Tresiba, Novo’s resubmission of Tresiba could backfire for a couple of reasons, say analysts. Tresiba has already launched in Europe, Mexico and Japan.
Insulin Nation
OCTOBER 7, 2014
Not everyone can use steroids for edema, however, as the treatment can sometimes put pressure on the eye or cause cataracts, according to a Fierce Biotech report. The news helps buoy Novo’s chances of getting FDA approval for Tresiba in the second half of 2015, according to FierceBiotech. Sanofi and Afrezza: A Dynamic Duo? Treatment'
Digital Health Global
MAY 24, 2023
Clin Infect Dis 69:2015–2018. ” “As an infectious disease doctor, I recognize the urgent need for new solutions in the fight against antimicrobial resistance. Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. 10.1093/cid/ciz222.
Expert insights. Personalized for you.
88 
Let's personalize your content